Literature DB >> 24710956

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

Timothy G Whitsett1, Shannon P Fortin Ensign, Harshil D Dhruv, Landon J Inge, Paul Kurywchak, Kerri K Wolf, Janine LoBello, Christopher B Kingsley, Jeffrey W Allen, Glen J Weiss, Nhan L Tran.   

Abstract

The five-year survival rate in advanced non-small cell lung cancer (NSCLC) remains below ten percent. The invasive and metastatic nature of NSCLC tumor cells contributes to the high mortality rate, and as such the mechanisms that govern NSCLC metastasis is an active area of investigation. Two surface receptors that influence NSCLC invasion and metastasis are the hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14). MET protein is over-expressed in NSCLC tumors and associated with poor clinical outcome and metastasis. FN14 protein is also elevated in NSCLC tumors and positively correlates with tumor cell migration and invasion. In this report, we show that MET and FN14 protein expressions are significantly correlated in human primary NSCLC tumors, and the protein levels of MET and FN14 are elevated in metastatic lesions relative to patient-matched primary tumors. In vitro, HGF/MET activation significantly enhances FN14 mRNA and protein expression. Importantly, depletion of FN14 is sufficient to inhibit MET-driven NSCLC tumor cell migration and invasion in vitro. This work suggests that MET and FN14 protein expressions are associated with the invasive and metastatic potential of NSCLC. Receptor-targeted therapeutics for both MET and FN14 are in clinical development, the use of which may mitigate the metastatic potential of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24710956     DOI: 10.1007/s10585-014-9653-6

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  SnapShot: non-small cell lung cancer.

Authors:  Rebecca S Heist; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.

Authors:  Nhan L Tran; Wendy S McDonough; Benjamin A Savitch; Thomas F Sawyer; Jeffrey A Winkles; Michael E Berens
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors.

Authors:  Rebeca Sanz-Pamplona; Ramón Aragüés; Keltouma Driouch; Berta Martín; Baldo Oliva; Miguel Gil; Susana Boluda; Pedro L Fernández; Antonio Martínez; Víctor Moreno; Juan J Acebes; Rosette Lidereau; Fabien Reyal; Marc J Van de Vijver; Angels Sierra
Journal:  Am J Pathol       Date:  2011-06-25       Impact factor: 4.307

5.  Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.

Authors:  Timothy G Whitsett; Emily Cheng; Landon Inge; Kaushal Asrani; Nathan M Jameson; Galen Hostetter; Glen J Weiss; Christopher B Kingsley; Joseph C Loftus; Ross Bremner; Nhan L Tran; Jeffrey A Winkles
Journal:  Am J Pathol       Date:  2012-05-23       Impact factor: 4.307

6.  The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas.

Authors:  S L Feng; Y Guo; V M Factor; S S Thorgeirsson; D W Bell; J R Testa; K A Peifley; J A Winkles
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

7.  The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2.

Authors:  Shannon P Fortin Ensign; Ian T Mathews; Jennifer M Eschbacher; Joseph C Loftus; Marc H Symons; Nhan L Tran
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

8.  Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.

Authors:  George S Watts; Nhan L Tran; Michael E Berens; Achyut K Bhattacharyya; Mark A Nelson; Elizabeth A Montgomery; Richard E Sampliner
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

Review 9.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

10.  The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Authors:  Hong Zhou; Suhendan Ekmekcioglu; John W Marks; Khalid A Mohamedali; Kaushal Asrani; Keeley K Phillips; Sharron A N Brown; Emily Cheng; Michele B Weiss; Walter N Hittelman; Nhan L Tran; Hideo Yagita; Jeffrey A Winkles; Michael G Rosenblum
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

View more
  7 in total

1.  Lower Expression of TWEAK is Associated with Poor Survival and Dysregulate TIICs in Lung Adenocarcinoma.

Authors:  Zhengxi He; Sai Wang; Jinchun Wu; Yangchun Xie; Bin Li
Journal:  Dis Markers       Date:  2022-06-06       Impact factor: 3.464

Review 2.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

3.  Transcriptomic and Functional Pathway Analysis of Human Cervical Carcinoma Cancer Cells Response to Microtubule Inhibitor.

Authors:  Jin Wang; Bin Yan; Song-Mei Liu; Huanhuan Sun; Yonglong Pan; Daogang Guan; Xiaoyan Zhang; Jianqing Xu; Haiqing Ma
Journal:  J Cancer       Date:  2015-07-29       Impact factor: 4.207

4.  A Putative Blood-Based Biomarker for Autism Spectrum Disorder-Associated Ileocolitis.

Authors:  Stephen J Walker; Daniel P Beavers; John Fortunato; Arthur Krigsman
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

5.  Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Authors:  Alison Roos; Harshil D Dhruv; Ian T Mathews; Landon J Inge; Serdar Tuncali; Lauren K Hartman; Donald Chow; Nghia Millard; Holly H Yin; Jean Kloss; Joseph C Loftus; Jeffrey A Winkles; Michael E Berens; Nhan L Tran
Journal:  Oncotarget       Date:  2017-02-14

6.  The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.

Authors:  Emily Cheng; Timothy G Whitsett; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2014-11-12       Impact factor: 5.852

7.  Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.

Authors:  Ana Alvarez de Cienfuegos; Lawrence H Cheung; Khalid A Mohamedali; Timothy G Whitsett; Jeffrey A Winkles; Walter N Hittelman; Michael G Rosenblum
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.